Edition:
United Kingdom

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

52.50USD
23 May 2018
Change (% chg)

$0.16 (+0.31%)
Prev Close
$52.34
Open
$52.34
Day's High
$52.62
Day's Low
$52.17
Volume
1,368,841
Avg. Vol
2,115,805
52-wk High
$70.04
52-wk Low
$49.97

Chart for

About

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small... (more)

Overall

Beta: 1.19
Market Cap(Mil.): $106,283.60
Shares Outstanding(Mil.): 1,639.93
Dividend: 0.39
Yield (%): 2.41

Financials

  BMY.N Industry Sector
P/E (TTM): 23.62 30.95 32.75
EPS (TTM): 2.74 -- --
ROI: 18.60 14.84 14.38
ROE: 30.97 16.34 16.07

BRIEF-Omega Advisors Takes Share Stake In UnitedHealth, Bristol-Myers Squibb

* OMEGA ADVISORS DISSOLVES SHARE STAKE IN AMERICAN AIRLINES - SEC FILING

15 May 2018

Setback to Roche hopes for Tecentriq as fails key cancer trial

ZURICH Roche's hopes of its Tecentriq immunotherapy catching rival medicines from Merck and Bristol-Myers Squibb were dealt a blow on Thursday after it failed a key combination trial.

10 May 2018

Roche's Tecentriq combo wins fast FDA review in race to catch rivals

ZURICH Roche's immunotherapy combination that includes Tecentriq, Avastin and chemotherapy will get an accelerated review by U.S. regulators for use as an initial treatment of a common form of lung cancer, the Swiss drugmaker said on Monday.

07 May 2018

UPDATE 1-Roche's Tecentriq combo wins fast FDA review in race to catch rivals

ZURICH, May 7 Roche's immunotherapy combination that includes Tecentriq, Avastin and chemotherapy will get an accelerated review by U.S. regulators for use as an initial treatment of a common form of lung cancer, the Swiss drugmaker said on Monday.

07 May 2018

BRIEF-Bristol-Myers Squibb Elects Each Of Company's 12 Nominees To Serve As Directors

* BRISTOL-MYERS SQUIBB CO - SHAREHOLDERS ELECTED EACH OF COMPANY'S 12 NOMINEES TO SERVE AS DIRECTORS OF COMPANY UNTIL 2019 ANNUAL MEETING

03 May 2018

BRIEF-EMA Validates Bristol-Myers' Type II Variation Application For Opdivo Plus Yervoy Combination For Treatment Of First-Line Metastatic Non-Small Cell Lung Cancer

* EUROPEAN MEDICINES AGENCY VALIDATES BRISTOL-MYERS SQUIBB'S TYPE II VARIATION APPLICATION FOR OPDIVO PLUS YERVOY COMBINATION FOR TREATMENT OF FIRST-LINE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)

03 May 2018

BRIEF-Bristol-Myers Squibb And Flatiron Health Expand Collaboration With A Three-Year Agreement

* BRISTOL-MYERS SQUIBB AND FLATIRON HEALTH EXPAND COLLABORATION WITH A THREE-YEAR AGREEMENT

02 May 2018

Keytruda sales power Merck to quarterly beat

Drugmaker Merck & Co reported better-than-expected first-quarter earnings on Tuesday, helped by a more than 150 percent rise in sales of blockbuster cancer drug Keytruda. | Video

01 May 2018

Keytruda sales power Merck to quarterly beat

Drugmaker Merck & Co reported better-than-expected first-quarter earnings on Tuesday, helped by a more than 150 percent rise in sales of blockbuster cancer drug Keytruda.

01 May 2018

UPDATE 3-Keytruda sales power Merck to quarterly beat

* Shares drop 2.8 pct (updates share price, adds analyst and CEO quote)

01 May 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $123.45 +0.54
Pfizer Inc. (PFE.N) $35.97 +0.25
Merck & Co., Inc. (MRK.N) $59.17 +0.72
Sanofi SA (SASY.PA) €66.23 -0.14
AstraZeneca plc (AZN.L) 5,454.00 0.00
GlaxoSmithKline plc (GSK.L) 1,507.60 -1.60
Eli Lilly And Co (LLY.N) $82.68 +0.46
Roche Holding Ltd. (ROG.S) CHF219.25 -4.65
Roche Holding Ltd. (RO.S) CHF223.40 -5.40

Earnings vs. Estimates